PDCD1LG2 and neoplasm: A tumor immune response is generated by sintilimab via binding to PD‐1 and blocking the binding of PD‐1 to programmed death‐ligand 1 (PD‐L1) and PD‐L2 thus removing the immunosuppressive effect, activating the function of T cells, and enhancing the immune surveillance and tumor‐killing ability of T cells.2